-
1دورية أكاديمية
المؤلفون: Piero Ruggenenti, Monica Cortinovis, Aneliya Parvanova, Matias Trillini, Ilian P Iliev, Antonio C Bossi, Antonio Belviso, Maria C Aparicio, Roberto Trevisan, Stefano Rota, Annalisa Perna, Tobia Peracchi, Nadia Rubis, Davide Martinetti, Silvia Prandini, Flavio Gaspari, Fabiola Carrara, Salvatore De Cosmo, Giancarlo Tonolo, Ruggero Mangili, Giuseppe Remuzzi, VARIETY Study Organization
المصدر: PLoS Medicine, Vol 18, Iss 7, p e1003691 (2021)
مصطلحات موضوعية: Medicine
وصف الملف: electronic resource
-
2دورية أكاديمية
المؤلفون: Piero Ruggenenti (180711), Monica Cortinovis (5399138), Aneliya Parvanova (11133325), Matias Trillini (6560225), Ilian P. Iliev (11133328), Antonio C. Bossi (9452934), Antonio Belviso (11133331), Maria C. Aparicio (11133334), Roberto Trevisan (499060), Stefano Rota (3834721), Annalisa Perna (6560222), Tobia Peracchi (11133337), Nadia Rubis (6560240), Davide Martinetti (10823998), Silvia Prandini (180731), Flavio Gaspari (180714), Fabiola Carrara (180719), Salvatore De Cosmo (158567), Giancarlo Tonolo (256228), Ruggero Mangili (11133340), Giuseppe Remuzzi (180748)
مصطلحات موضوعية: Medicine, Physiology, Pharmacology, Biotechnology, Marine Biology, Cancer, Infectious Diseases, Virology, microalbuminuria, RAS, BP, ACE, acceleration factors, 612 type 2, combination therapy, benazepril, VARIETY, valsartan, normoalbuminuric type 2, failure time model, Istituto di Ricerche Farmacologiche., angiotensin receptor blockers, CI, combination therapy group, study Background Angiotensin, mg, PROBE, IQR, ClinicalTrials.gov NCT 00503152, Trial registration EudraCT 2006-005.
-
3دورية أكاديمية
المؤلفون: Piero Ruggenenti (180711), Monica Cortinovis (5399138), Aneliya Parvanova (11133325), Matias Trillini (6560225), Ilian P. Iliev (11133328), Antonio C. Bossi (9452934), Antonio Belviso (11133331), Maria C. Aparicio (11133334), Roberto Trevisan (499060), Stefano Rota (3834721), Annalisa Perna (6560222), Tobia Peracchi (11133337), Nadia Rubis (6560240), Davide Martinetti (10823998), Silvia Prandini (180731), Flavio Gaspari (180714), Fabiola Carrara (180719), Salvatore De Cosmo (158567), Giancarlo Tonolo (256228), Ruggero Mangili (11133340), Giuseppe Remuzzi (180748)
مصطلحات موضوعية: Medicine, Physiology, Pharmacology, Biotechnology, Marine Biology, Cancer, Infectious Diseases, Virology, microalbuminuria, RAS, BP, ACE, acceleration factors, 612 type 2, combination therapy, benazepril, VARIETY, valsartan, normoalbuminuric type 2, failure time model, Istituto di Ricerche Farmacologiche., angiotensin receptor blockers, CI, combination therapy group, study Background Angiotensin, mg, PROBE, IQR, ClinicalTrials.gov NCT 00503152, Trial registration EudraCT 2006-005.
-
4دورية أكاديمية
المؤلفون: Piero Ruggenenti (180711), Monica Cortinovis (5399138), Aneliya Parvanova (11133325), Matias Trillini (6560225), Ilian P. Iliev (11133328), Antonio C. Bossi (9452934), Antonio Belviso (11133331), Maria C. Aparicio (11133334), Roberto Trevisan (499060), Stefano Rota (3834721), Annalisa Perna (6560222), Tobia Peracchi (11133337), Nadia Rubis (6560240), Davide Martinetti (10823998), Silvia Prandini (180731), Flavio Gaspari (180714), Fabiola Carrara (180719), Salvatore De Cosmo (158567), Giancarlo Tonolo (256228), Ruggero Mangili (11133340), Giuseppe Remuzzi (180748)
مصطلحات موضوعية: Medicine, Physiology, Pharmacology, Biotechnology, Marine Biology, Cancer, Infectious Diseases, Virology, microalbuminuria, RAS, BP, ACE, acceleration factors, 612 type 2, combination therapy, benazepril, VARIETY, valsartan, normoalbuminuric type 2, failure time model, Istituto di Ricerche Farmacologiche., angiotensin receptor blockers, CI, combination therapy group, study Background Angiotensin, mg, PROBE, IQR, ClinicalTrials.gov NCT 00503152, Trial registration EudraCT 2006-005.
-
5دورية أكاديمية
المؤلفون: Piero Ruggenenti (180711), Monica Cortinovis (5399138), Aneliya Parvanova (11133325), Matias Trillini (6560225), Ilian P. Iliev (11133328), Antonio C. Bossi (9452934), Antonio Belviso (11133331), Maria C. Aparicio (11133334), Roberto Trevisan (499060), Stefano Rota (3834721), Annalisa Perna (6560222), Tobia Peracchi (11133337), Nadia Rubis (6560240), Davide Martinetti (10823998), Silvia Prandini (180731), Flavio Gaspari (180714), Fabiola Carrara (180719), Salvatore De Cosmo (158567), Giancarlo Tonolo (256228), Ruggero Mangili (11133340), Giuseppe Remuzzi (180748)
مصطلحات موضوعية: Medicine, Physiology, Pharmacology, Biotechnology, Marine Biology, Cancer, Infectious Diseases, Virology, microalbuminuria, RAS, BP, ACE, acceleration factors, 612 type 2, combination therapy, benazepril, VARIETY, valsartan, normoalbuminuric type 2, failure time model, Istituto di Ricerche Farmacologiche., angiotensin receptor blockers, CI, combination therapy group, study Background Angiotensin, mg, PROBE, IQR, ClinicalTrials.gov NCT 00503152, Trial registration EudraCT 2006-005.
-
6دورية أكاديمية
المؤلفون: Piero Ruggenenti (180711), Monica Cortinovis (5399138), Aneliya Parvanova (11133325), Matias Trillini (6560225), Ilian P. Iliev (11133328), Antonio C. Bossi (9452934), Antonio Belviso (11133331), Maria C. Aparicio (11133334), Roberto Trevisan (499060), Stefano Rota (3834721), Annalisa Perna (6560222), Tobia Peracchi (11133337), Nadia Rubis (6560240), Davide Martinetti (10823998), Silvia Prandini (180731), Flavio Gaspari (180714), Fabiola Carrara (180719), Salvatore De Cosmo (158567), Giancarlo Tonolo (256228), Ruggero Mangili (11133340), Giuseppe Remuzzi (180748)
مصطلحات موضوعية: Medicine, Physiology, Pharmacology, Biotechnology, Marine Biology, Cancer, Infectious Diseases, Virology, microalbuminuria, RAS, BP, ACE, acceleration factors, 612 type 2, combination therapy, benazepril, VARIETY, valsartan, normoalbuminuric type 2, failure time model, Istituto di Ricerche Farmacologiche., angiotensin receptor blockers, CI, combination therapy group, study Background Angiotensin, mg, PROBE, IQR, ClinicalTrials.gov NCT 00503152, Trial registration EudraCT 2006-005.
العلاقة: https://figshare.com/articles/journal_contribution/VARIETY_Study_Organization_/14981719Test
-
7دورية أكاديمية
المؤلفون: Piero Ruggenenti (180711), Monica Cortinovis (5399138), Aneliya Parvanova (11133325), Matias Trillini (6560225), Ilian P. Iliev (11133328), Antonio C. Bossi (9452934), Antonio Belviso (11133331), Maria C. Aparicio (11133334), Roberto Trevisan (499060), Stefano Rota (3834721), Annalisa Perna (6560222), Tobia Peracchi (11133337), Nadia Rubis (6560240), Davide Martinetti (10823998), Silvia Prandini (180731), Flavio Gaspari (180714), Fabiola Carrara (180719), Salvatore De Cosmo (158567), Giancarlo Tonolo (256228), Ruggero Mangili (11133340), Giuseppe Remuzzi (180748)
مصطلحات موضوعية: Medicine, Physiology, Pharmacology, Biotechnology, Marine Biology, Cancer, Infectious Diseases, Virology, microalbuminuria, RAS, BP, ACE, acceleration factors, 612 type 2, combination therapy, benazepril, VARIETY, valsartan, normoalbuminuric type 2, failure time model, Istituto di Ricerche Farmacologiche., angiotensin receptor blockers, CI, combination therapy group, study Background Angiotensin, mg, PROBE, IQR, ClinicalTrials.gov NCT 00503152, Trial registration EudraCT 2006-005.
-
8دورية أكاديمية
المؤلفون: Piero Ruggenenti (180711), Monica Cortinovis (5399138), Aneliya Parvanova (11133325), Matias Trillini (6560225), Ilian P. Iliev (11133328), Antonio C. Bossi (9452934), Antonio Belviso (11133331), Maria C. Aparicio (11133334), Roberto Trevisan (499060), Stefano Rota (3834721), Annalisa Perna (6560222), Tobia Peracchi (11133337), Nadia Rubis (6560240), Davide Martinetti (10823998), Silvia Prandini (180731), Flavio Gaspari (180714), Fabiola Carrara (180719), Salvatore De Cosmo (158567), Giancarlo Tonolo (256228), Ruggero Mangili (11133340), Giuseppe Remuzzi (180748)
مصطلحات موضوعية: Medicine, Physiology, Pharmacology, Biotechnology, Marine Biology, Cancer, Infectious Diseases, Virology, microalbuminuria, RAS, BP, ACE, acceleration factors, 612 type 2, combination therapy, benazepril, VARIETY, valsartan, normoalbuminuric type 2, failure time model, Istituto di Ricerche Farmacologiche., angiotensin receptor blockers, CI, combination therapy group, study Background Angiotensin, mg, PROBE, IQR, ClinicalTrials.gov NCT 00503152, Trial registration EudraCT 2006-005.
-
9صورة
المؤلفون: Piero Ruggenenti (180711), Monica Cortinovis (5399138), Aneliya Parvanova (11133325), Matias Trillini (6560225), Ilian P. Iliev (11133328), Antonio C. Bossi (9452934), Antonio Belviso (11133331), Maria C. Aparicio (11133334), Roberto Trevisan (499060), Stefano Rota (3834721), Annalisa Perna (6560222), Tobia Peracchi (11133337), Nadia Rubis (6560240), Davide Martinetti (10823998), Silvia Prandini (180731), Flavio Gaspari (180714), Fabiola Carrara (180719), Salvatore De Cosmo (158567), Giancarlo Tonolo (256228), Ruggero Mangili (11133340), Giuseppe Remuzzi (180748)
مصطلحات موضوعية: Medicine, Physiology, Pharmacology, Biotechnology, Marine Biology, Cancer, Infectious Diseases, Virology, microalbuminuria, RAS, BP, ACE, acceleration factors, 612 type 2, combination therapy, benazepril, VARIETY, valsartan, normoalbuminuric type 2, failure time model, Istituto di Ricerche Farmacologiche., angiotensin receptor blockers, CI, combination therapy group, study Background Angiotensin, mg, PROBE, IQR, ClinicalTrials.gov NCT 00503152, Trial registration EudraCT 2006-005.
-
10صورة
المؤلفون: Piero Ruggenenti (180711), Monica Cortinovis (5399138), Aneliya Parvanova (11133325), Matias Trillini (6560225), Ilian P. Iliev (11133328), Antonio C. Bossi (9452934), Antonio Belviso (11133331), Maria C. Aparicio (11133334), Roberto Trevisan (499060), Stefano Rota (3834721), Annalisa Perna (6560222), Tobia Peracchi (11133337), Nadia Rubis (6560240), Davide Martinetti (10823998), Silvia Prandini (180731), Flavio Gaspari (180714), Fabiola Carrara (180719), Salvatore De Cosmo (158567), Giancarlo Tonolo (256228), Ruggero Mangili (11133340), Giuseppe Remuzzi (180748)
مصطلحات موضوعية: Medicine, Physiology, Pharmacology, Biotechnology, Marine Biology, Cancer, Infectious Diseases, Virology, microalbuminuria, RAS, BP, ACE, acceleration factors, 612 type 2, combination therapy, benazepril, VARIETY, valsartan, normoalbuminuric type 2, failure time model, Istituto di Ricerche Farmacologiche., angiotensin receptor blockers, CI, combination therapy group, study Background Angiotensin, mg, PROBE, IQR, ClinicalTrials.gov NCT 00503152, Trial registration EudraCT 2006-005.